Clinical Trial

Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 12, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single armed, Phase 3 study to assess the immunogenicity and safety of the varicella vaccine manufactured by Sinovac. A total of 300 healthy participants aged 1-12 years will be enrolled. All participants will receive a single dose of varicella vaccine manufactured by Sinovac.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-11.
Trial Details
NCT Number NCT07473427
Lead Sponsor Sinovac (Dalian) Vaccine Technology Co., Ltd.
Conditions Varicella (Chickenpox), Varicella Immunisation
Enrollment 300 participants
Start Date 2026-06-15
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-12